TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: VIT-ARMin Virtual, Intensified and Patient-tailored Robotic Arm Therapy With the Exoskeleton Robot ARMin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~healthy or CVA or spinal cord injury~* Aged ≥18 years~* No excessive spasticity of the affected arm (modified Ashworth Scale ≤3)~* No serious medical or psychiatric disorder as assessed by their physician~* No orthopaedic, rheumatological, or other disease restricting movements of the paretic arm~* No shoulder subluxation (palpation \<2 fingers)~* No skin ulcerations at the paretic arm~* Ability to communicate effectively with the examiner such that the validity of the patient's data could not be compromised~* No cybersickness (e.g., nausea when looking at a screen or playing computer games)~* No pacemaker or other implanted electric devices~* Bodyweight \<120 kg~* No serious cognitive defects or aphasia preventing effective use of ARMin~Exclusion Criteria~- Allergy against alcohol or no agreement for skin shaving

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ARMin (Type: EXPERIMENTAL): Therapy on ARMin robotic device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinically definite diagnosis of NF1 according to the NIH consensus conference criteria.~2. Patients must have PN that have the potential to cause significant morbidity, such as lesions that could compromise the airway or the great vessels, lesions that could cause nerve compression, lesions that could result in major deformity or significant cosmetic problems~3. Measurable disease: patient must have at least one measurable PN amenable to volumetric MRI analysis.~Exclusion Criteria:~1. Chronic treatment with systemic steroids or another immunosuppressive agent.~2. Evidence of an active optic glioma, malignant glioma, malignant peripheral nerve sheath tumor, or other cancer requiring treatment with chemotherapy or radiation therapy.~3. Clinical evidence of significantly impaired lung function~4. Pregnancy or breast feeding.~5. Prior therapy with mTOR inhibitors (e.g.sirolimus, temsirolimus, everolimus).~6. No contraindications for MRI assessments~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (RAD001) (Type: EXPERIMENTAL): enrolled patients received everolimus (RAD001) in an open label manner. Recommended starting dose of everolimus depend on body surface area, starting from 2.5 mg once daily to 7.5 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants having an Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0 - 1~* Histologically confirmed diagnosis in previously untreated Locally Advanced Squamous Cell Carcinoma of Head and neck (LA SCCHN) patient (Stage III, IVA, or IVB according to the American Joint Committee on Cancer \[AJCC\]/ Tumor Nodes and metastases (TNM) Staging System, 8th Edition) suitable for definitive Chemoradiotherapy (CRT), with one of the following primary sites: oropharynx (OPC) Human Papillomavirus (HPV)-negative, hypopharynx, and larynx~* Participant should be able to swallow liquids or has an adequately functioning feeding tube, gastrostomy, or jejunostomy in place. For participants requiring liquid nutrition at baseline or during the study including the follow-up period, access to liquid nutrition supply should be ensured~* Participant with evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by CT scan and/or MRI, based on RECIST v 1.1.~* Adequate hematological, hepatic, and renal function as defined in the protocol~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Primary tumor of nasopharyngeal, paranasal sinuses, nasal, or oral cavity, salivary, thyroid, or parathyroid gland pathologies, skin, or unknown primary site~* Metastatic disease (Stage IVC as per AJCC/TNM, 8th Edition)~* Existing need of a hearing aid or greater than or equal to (\>=) 25 decibel shift over 2 contiguous frequencies on a pretreatment hearing test as clinically indicated~* Known history of infection with human immunodeficiency virus (HIV). If unknown history of HIV, an HIV screening test is to be performed and participants with positive serology for HIV-1/2 must be excluded~* Known gastrointestinal disorder with clinically established malabsorption syndrome and major gastrointestinal surgery in the last 12 months that may limit oral absorption~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xevinapant + Cisplatin + IMRT (Type: EXPERIMENTAL): Participants will receive xevinapant once daily from Day 1 to Day 14, per 3-week cycle (Each cycle is of 3 weeks). The first three cycles are given in combination with weekly cisplatin and radiotherapy, followed by 3 cycles of monotherapy xevinapant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with severe DILI (Drug Induced Liver Injury)~* Age more than or equal to 18 years~Exclusion Criteria:~* Patients with HAV (Hepatitis A Virus), HBV (Hepatitis B Virus), HCV (Hepatitis C Virus), HEV (Hepatitis E Virus) Positive~* Patients with sepsis~* AMA positive~* Low Ceruloplasmin~* Transferrin saturation \>45%~* Patients with Cirrhosis~* Patients with h/o jaundice prior to the intake of drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prednisolone + N-Acetylcysteine (Type: EXPERIMENTAL): Prednisolone for 20 days with NAC (N-Acetylcysteine) NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
- N-Acetylcysteine (Type: ACTIVE_COMPARATOR): NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have SCD \[homozygous sickle cell (HbSS) or hemoglobin (HbS) Beta\^0 thalassemia\]~* Are participants with SCD who have had ≥2 episodes of vaso-occlusive crisis (VOC) in the past year~* Have a body weight ≥19 kilograms (kg) and are ≥2 and \<18 years of age, inclusive at the time of screening~* If participants are ≥2 and ≤16 years of age, must have had a transcranial Doppler within the last year~Exclusion Criteria:~* History of: transient ischemic attack (TIA)/ ischemic or hemorrhagic stroke, severe head trauma, intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm~* History of abnormal or conditional \[velocity in middle or anterior cerebral, or internal carotid artery ≥170 centimeter per second (cm/sec)\] transcranial Doppler within the last year~* History of, or are undergoing treatment with, chronic red blood cell (RBC) transfusion therapy~* Are at an increased risk for bleeding complications~* Are receiving chronic treatment with nonsteroidal anti-inflammatory drug (NSAID)s and cannot be switched to another analgesic

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: EXPERIMENTAL): Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.
- Placebo (Type: PLACEBO_COMPARATOR): Participants in this treatment group will receive daily orally administered placebo and will follow visit schedule identical to that in the active treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Electromagnetic Stimulation of the Phrenic Nerve in Critically Ill Mechanically Ventilated Patients (STIMIT-II)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 and 60 years old, hospitalized in ICU~* Mechanical ventilation \< 36 h~* Prone to stay ventilated \> 72 h~Exclusion Criteria:~* Known neurological condition affecting motor neuron or muscle (e.g. ALS)~* Known paralysis of the phrenic nerve~* Proven or suspected spinal cord injury that contraindicates weight bearing on the spinal cord~* Conditions that limit diaphragm movement (high intra-abdominal pressure, ascites, obesity)~* Not able to read and understand the national language German~* Patients with Implanted cardiac support systems (pacemaker, implanted defibrillator)~* Patients with implanted medical pumps~* Pregnant patients~* Patients with skin lesions, infections or strictures in throat/neck area~* Patients with metallic implants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention, stimulated (Type: EXPERIMENTAL): Electromagnetic stimulation of the phrenic nerve in critically ill patients.
- Control, not stimulated (Type: NO_INTERVENTION): Control group, no stimulation of the phrenic nerve.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Remediation in Early Substance Abuse Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans participating in a substance abuse day treatment program at the Errara Community Center~Exclusion Criteria:

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): PSS CogRehab exercises
- 2 (Type: NO_INTERVENTION): On-line computer games

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant born at gestational age less than 34 weeks~* Birth weight less than 2500 grams~* Diagnosis of stage II or III NEC made by attending neonatologist, neonatology fellow, or pediatric hospitalist~* Legally authorized representative is able to provide written informed consent prior to the performance of an protocol-specified evaluations or procedures~* Consent can be obtained and study drug can be administered within 6 hours of diagnosis~Exclusion Criteria:~* congenital gastrointestinal anomaly~* subject is already receiving parenteral steroid therapy or subject has received parenteral steroids within one week prior to study entry~* subject has received indomethacin therapy within 48 hours prior to being diagnosed with NEC

- Gender: ALL
- Minimum Age: 0 Days
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- hydrocortisone (Type: EXPERIMENTAL): Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via intravenous (IV) route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. Subjects in placebo group will receive equal volume of placebo on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in placebo group will receive equal volume of placebo (as compared to hydrocortisone arm) on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 3D Versus Robot Assisted Laparoscopic Prostatectomy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Localized prostate cancer undergoing radical prostatectomy~* Patient has to understand and be able to write and read Finnish language~* No prior head injury, dementia or Parkinson's disease~* No concomitant malignant illness~* Life expectancy of at least 10 years~* 35-74 years of age~Exclusion Criteria:~* Locally advanced prostate cancer (T4)~* Suspicion or documented metastases (M1)~* Serum PSA \> 20 ng/ml~* Prior laparoscopic hernia surgery employing non resorbable mesh~* Prior pelvic irradiation or major surgery~* Prior malignant disease within prior 5 years excluding skin cancer (non-melanoma).

- Gender: MALE
- Minimum Age: 34 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Robot assisted prostatectomy. (Type: ACTIVE_COMPARATOR): Intervention: radical prostatectomy
- 3D laparoscopic prostatectomy (Type: EXPERIMENTAL): Intervention: radical prostatectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with histopathological confirmation of primary (or recurrent) invasive breast carcinoma and distant metastatic disease at diagnosis.~* Target tumor size ≤ 3.0 cm (T1-2b category);~* Morphological type: invasive breast cancer~* Luminal-type A (ER+, PR+, Her2/neu +1), HER+, luminal-type B (ER +/-, PR +/-, Her2/neu+1), or Triple negative breast carcinoma~* Measurable disease according to RECIST v1.1.~* Subjects over 45 years old.~* Subjects' ECOG Performance Status Scale is \< 2.~* Subjects' life expectancy more than 6 months.~* Platelet count ≥100,000/mm3.~* International normalized ratio of prothrombin time ≤1.8.~* Creatinine ≤1.9 mg/dL.~* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test.~* Subjects are willing to sign an informed consent form.~Exclusion Criteria:~* T4 category with skin involvement.~* Regional lymph node metastases.~* Ductal carcinoma in situ.~* Inflammatory breast carcinoma.~* Patients with pre-irradiation of the breast.~* Acute infection disease.~* The presence of HIV, RW, HbsAg, HCV in the acute stage.~* Pregnancy or lactation.~* Serious competing (somatic) diseases incompatible according to the researcher with brachytherapy.~* Mental illness.~* Patients undergoing immunosuppressive and/or systemic corticosteroid treatment~* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.~* High probability of protocol non-compliance (in opinion of investigator).~* Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)~* Subjects not willing to sign an informed consent.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DaRT Seeds (Type: EXPERIMENTAL): Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who would benefit from a posterior vitreous detachment, as determined by the evaluating ophthalmologist.~Exclusion Criteria:~* Presence of a posterior vitreous detachment in the study eye~* History of vitrectomy in the study eye~* Proliferative diabetic retinopathy in the study eye~* Presence of media opacity that precludes quality examination of the vitreous and fundus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plasmin Injection (Type: EXPERIMENTAL): human-derived plasmin
- Vehicle (Type: PLACEBO_COMPARATOR): Plasmin formulation, without active ingredient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Drainless Robot-assisted Minimally Invasive Esophagectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for elective RAMIE for esophageal cancer with intrathoracic esophagogastrostomy (Ivor-Lewis)~* American Society of Anesthesiologists (ASA) score ≤ III~* Eastern Cooperative of Oncology Group (ECOG) status ≤ II~* Patient suitable for both surgical techniques~* Ability of subject to understand character and individual consequences of the clinical trial~* Written informed consent~Exclusion Criteria:~* Open esophagectomy (either abdominal or during the thoracic part)~* Emergency operations~* ASA IV~* ECOG \> II~* Chronic pain syndromes requiring routine analgesics~* Simultaneous lung resection~* Presence of contraindications to the use of epidural anesthesia (e.g. coagulopathies, anticoagulation or allergies)~* Participation in an interventional trial, which interferes with the outcome~* Impaired mental state

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A - Early removal of chest drain (Type: EXPERIMENTAL): None
- B - Control (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older,~* Scheduled to undergo fiducial placement,~* Subject must be able to give informed consent~Exclusion Criteria:~* Any contraindication to performing endoscopy,~* Participation in another research protocol that could interfere or influence the outcomes measures of the present study,~* The subject is unable/unwilling to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects requiring fiducial placement (Type: None): Endoscopic Ultrasound (EUS) for fiducial placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues